Please ensure Javascript is enabled for purposes of website accessibility

Here’s Why Emergent BioSolutions Is Rising Today

By Prosper Junior Bakiny – Apr 24, 2020 at 12:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company signed a deal to help manufacture Johnson & Johnson’s lead COVID-19 vaccine candidate.

What happened

Shares of Emergent BioSolutions (EBS -3.69%) were up by 8% as of 12:08 p.m. EDT on Friday. The market is likely responding to the news that Emergent BioSolutions signed a $135 million contract with Johnson & Johnson (JNJ -0.61%). Per the terms of the agreement between the two entities, Emergent BioSolutions -- which manufactures pharmaceutical products for other companies -- will be tasked with manufacturing Johnson & Johnson's investigational COVID-19 vaccine.

So what

Johnson & Johnson said it was aiming to supply more than 1 billion doses of its lead vaccine candidate for COVID-19. Emergent BioSolutions will use its facilities to help ramp up the manufacturing of Johnson & Johnson's vaccine. It is, however, worth noting that Johnson & Johnson's candidate hasn't even reached the clinical trial phase yet.

The pharma giant said it was looking to start clinical trials by September. Johnson & Johnson is hoping to have its potential COVID-19 vaccine ready for emergency use in early 2021, an ambitious goal considering vaccine candidates typically take much longer than that to be approved.

Gloved hand holding test tube containing blood for coronavirus testing.

Image Source: Getty Images.

Now what

Emergent BioSolutions has signed several other COVID-19-related deals. For instance, the company partnered up with Novavax (NVAX -10.14%) to help manufacture Novavax's potential vaccine for the novel coronavirus. Emergent BioSolutions penned a similar deal with Vaxart (VXRT -0.48%), which will see Emergent produce Vaxart's potential vaccine for COVID-19. The financial details of these deals were not disclosed.

While these partnerships are good news for Emergent BioSolutions, investors should temper their expectations. Given that there are at least 70 potential COVID-19 vaccines currently in development -- and most of them will probably never make it to the market -- buying shares of Emergent BioSolutions because of its involvement in the efforts to develop a vaccine for COVID-19 seems risky. There might be good reasons to invest in the biotech company, but this isn't one of them.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
EBS
$20.09 (-3.69%) $0.77
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$165.70 (-0.61%) $-1.02
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$18.87 (-10.14%) $-2.13
Vaxart, Inc. Stock Quote
Vaxart, Inc.
VXRT
$2.09 (-0.48%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.